Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

celgene europe ltd. - romidepsin - limfoma, mhux hodgkin - aġenti antineoplastiċi - it-trattament ta ' t-cell lymphoma (ptcl),.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

galpharm healthcare ltd. - sumatriptan succinate - disturbi fl-emigranja

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

biomimetic therapeutics ltd - becaplermin - riġenerazzjoni tat-tessuti iggwidata, perjodontali

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

elan pharma international ltd. - natalizumab - marda ta 'crohn - immunostimulanti, - it-trattament ta attiva minn moderata sa gravi marda ta 'crohn għat-tnaqqis ta' sinjali u sintomi, u l-induzzjoni u l-manteniment ta ' rispons u remissjoni, fl-pazjenti li ma kellhomx rispons minkejja sħiħ u adegwat matul it-terapija b'kortikosterojde u l-immunosuppressant; jew li huma intolleranti għal, jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

wyeth europa ltd - gemtuzumab ozogamicin - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - mill-ġdid tal-kura ta 'induzzjoni ta cd33-pożittivi aml f'pazjenti adulti fl-ewwel rikaduta li mhumiex kandidati għall-oħra intensiv mill-ġdid l-induzzjoni ta' kimoterapija (e. doża għolja ara-c) u tissodisfax mill-inqas wieħed mill-kriterji li ġejjin: t-tul ta'l-ewwel remissjoni 60 sena.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malarja - antiprotozoali - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antimalarial.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - aġenti antineoplastiċi - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

extrovis eu ltd. - lacosamide - epilessija - anti-epilettiċi, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.

Europos Sąjunga - maltiečių - EMA (European Medicines Agency)

radius health ireland ltd - abaloparatide - l-osteoporożi - homeostasi tal-kalċju - trattament ta 'l-osteoporożi.